Table 2. Ongoing clinical investigations targeting immune checkpoint blockade in gastric and esophageal cancer.
Study population | Histology | Number of samples | PD-L1 positive (%) | Outcome | Reference |
---|---|---|---|---|---|
Esophageal | Squamous | 41 | 44 | Worse outcomes | (30) |
Gastric | Adenocarcinoma | 102 | 42.2 | Nodal mets, advanced stage | (31) |
Adenocarcinoma | 111 | 63 | Advanced stage, worse outcome | (32) | |
Adenocarcinoma | 243 | 43.6 | Improved DFS, lower stage | (49) |
PD-L1, programmed death ligand 1; DFS, disease free survival.